Fort Washington Investment Advisors Inc. OH Sells 35,220 Shares of Haemonetics Co. (NYSE:HAE)

Fort Washington Investment Advisors Inc. OH decreased its holdings in Haemonetics Co. (NYSE:HAE) by 11.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 274,130 shares of the medical instruments supplier’s stock after selling 35,220 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in Haemonetics were worth $21,404,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Quarry LP bought a new stake in shares of Haemonetics in the 2nd quarter valued at approximately $39,000. Canada Pension Plan Investment Board bought a new stake in Haemonetics in the second quarter worth $83,000. Nisa Investment Advisors LLC boosted its stake in Haemonetics by 124.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after buying an additional 632 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Haemonetics during the second quarter valued at $140,000. Finally, iSAM Funds UK Ltd purchased a new stake in shares of Haemonetics in the third quarter valued at $204,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Down 2.5 %

NYSE HAE opened at $73.33 on Thursday. The company’s 50-day simple moving average is $81.35 and its two-hundred day simple moving average is $80.09. Haemonetics Co. has a one year low of $69.29 and a one year high of $97.97. The company has a market capitalization of $3.68 billion, a price-to-earnings ratio of 30.43, a price-to-earnings-growth ratio of 1.14 and a beta of 0.41. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. The company had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. Haemonetics’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.99 earnings per share. Equities analysts forecast that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on HAE shares. Raymond James raised shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target for the company in a research note on Friday, November 8th. JPMorgan Chase & Co. began coverage on Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and issued a $112.00 target price on shares of Haemonetics in a research note on Tuesday, December 3rd. Finally, Barrington Research reiterated an “outperform” rating and set a $108.00 target price on shares of Haemonetics in a research report on Wednesday, December 4th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Haemonetics presently has a consensus rating of “Moderate Buy” and an average price target of $108.78.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.